You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm plans to use the net proceeds for general corporate purposes, including working capital and capital expenditures.
The San Diego-based company said it plans to use the funds to speed development of its ProteoCode proteomics platform.
The Seattle-based University of Washington spinout is planning to scale up the commercial roll-out of its single-cell, whole-transcriptome assay kit.
The funding will be used to provide free at-home DNA tests to individuals with Long COVID, as well as to advance Sano's data-sharing platform.
OncoHost will use the funding to finance clinical trials, open a US location, and prepare to launch its proteomics platform called Prophet.
The company said it would use the funding in part to expand its commercial teams in the US and China, as well as to pursue Chinese regulatory approvals.
The firm will use funds from the round, which consists of $85 million in equity securities and a $50 million credit facility, to expand global sales and production.
The joint venture will further develop, manufacture, and distribute LevitasBio's magnetic levitation-based cell separation and purification platform in China.
The company, known for providing hereditary risk testing for cancer and cardiovascular conditions, has expanded into SARS-CoV-2 testing.
In early 2020, the direct-to-consumer genetic test developer laid off about 14 percent of its workforce amid a restructuring of its consumer business.
NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.
According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.
In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.
Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.